Antigen rapid tests are self-tests for Covid-19 which require no additional equipment. This means they are perfectly suited for low-resource areas where access to a laboratory and its equipment is limited or non existing.
“Antigen Rapid Detection Tests can both fill gaps in access to testing and alleviate pressure on laboratories performing NAAT, thereby reducing delays in diagnosis and optimizing use of available tools.” – World Health Organization (WHO)
The NEWGENE antigen detection kit is one of the most reliable rapid tests on the market, with an overall reliability of >97% in relation to the standard PCR test. For this reason, it is placed on the Paul Erlich Institut’s “Overview of SARS-CoV-2 Antigen Rapid Tests Assessed as Reflecting the Current State of the Art”. (PEI)
“COVID-19 antigen tests can deliver rapid and actionable results, ensuring timely identification of people infected with the virus at the community level. With the availability of more affordable quality rapid tests, countries must now scale up COVID-19 testing in the communities using rapid tests as well as centralised molecular testing wherever possible.” – Médecins Sans Frontières (MSF)
Although a >97% reliable answer may sound extremely high, there is still a possibility of false-negatives. Everyone should continue following infection control measures, regardless of a negative test.
Antigen tests are designed to reduce infection-numbers by detecting Covid infection in the early stages, through regularly administering self-tests. The rapid diagnosis of SARS-CoV-2 patients is essential to reduce the disease spread. Access to such an accurate test as the NEWGENE antigen test drastically increases the chances to diagnose Covid infection in the early stages, making it a key tool to prevent further transmission. The mission was to make covid-testing comfortable, accessible and easy to take. We wanted to ensure that people can ease themselves of some of the uncertainty the pandemic has brought about. None of us wants to unknowingly infect someone.
This thought leaves many paralyzed. However, this pandemic, no matter how much quarantine we’re induced to, isn’t resolved by inaction. It requires foresight, effective tools and an understanding of how complex a pandemic brought about in the 21st century – with it’s fast trains and planes – is. Without reliable measures at hand, someone about to step on a plane in New York can infect someone in Shanghai 10 hours from now. The twenty-first century is fast paced, crowded and hectic. The likelihood of transmission goes far beyond that which was present during the spanish flu just over 100 years ago. The world has evolved, and natural threats such as this have evolved with it. Thankfully, the equipment we have at our disposal evolve as well.
Someone once said that “it is through adversity that we overcome”. This pandemic has certainly brought about many adversities. Nevertheless, we must – and if we work together, we will – overcome. Right now, we are far closer to having the means to do so than just 6 months ago. From all over the world, bright minds have come together to further the technology needed to reduce transmissions which yielded massive progress in antigen-technology.
“A lower sensitivity can be tolerated in this context and compensated for by higher availability, higher turnaround time and repeated testing.” -Norwegian Directorate of Health (NDH)
The abovementioned quote was in regard to a study of a rapid antigen test with a sensitivity of only 79.8%, and the conclusion still ran as follows: “RATs may prove to be valuable tools in controlling the COVID-19 pandemic.”.
The NEWGENE rapid test has a sensitivity of >97% and is certain to be a most valuable tool in the fight against SARS-CoV-2.
World Health Organization. “Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays” – 11 september 2020. WHO: WHO/2019-nCoV/Antigen_Detection/2020.1
Paul Erlich Institut. “Comparative evaluation of the sensitivities of SARSCoV-2 antigen rapid tests” – 16 april 2021. PEI: https://www.pei.de/SharedDocs/Downloads/EN/newsroom-en/dossiers/evaluation-sars-cov2-antigen-tests-overview-04-12-2020.pdf?__blob=publicationFile&v=9 (downloaded 4th May 2021)
Medisins Sans Frontiers. “COVID-19 diagnostics: MSF welcomes more affordable rapid tests for lower- and middle-income countries “ – January 29, 2021. MSF: https://msf-access-campaign.prezly.com/covid-19-diagnostics-msf-welcomes-more-affordable-rapid-tests-for-lower-and-middle-income-countries (downloaded 4th May 2021)
Norwegian Directorate of Health. “COVID-19 pandemic: Evaluation of Abbot’s Panbio COVID-19 rapid antigen test in Norway” – 3 December 2020. NDH: https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-covid-19-rapid-antigen-test-in-norway/Evaluation%20of%20Abbots%20Panbio%20COVID-19%20rapid%20antigen%20test%20in%20Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-